Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tysabri in Early Relapsing Remitting Multiple Sclerosis Patients - TYPIFI (Tysabri Patient Initiation After Failure of the Initial DMT)

NCT04832399 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT04832399
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04832399 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tysabri in Early Relapsing Remitting Multiple Sclerosis Patients - TYPIFI (Tysabri Patient Initiation After Failure of the Initial DMT)
Lead sponsor
Biogen
Phase
Observational
Overall status
Completed
Start date
November 12, 2013
Completion date
October 2, 2023
Enrollment
60 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing remitting multiple sclerosis